Showing
1 changed file
with
455 additions
and
0 deletions
corpora/abstracts-titles-annotated.txt
0 → 100644
| 1 | +Assessment of the effect of potential antifibrotic compounds on total and aVb6 integrin-mediated TGF-b <v>activation.</v> | ||
| 2 | +M2 macrophages <v>induce </v><g>EMT</g> through the <g>TGF-b</g>/<g>Smad2</g> signaling pathway | ||
| 3 | +Resveratrol inhibits transforming growth factor-b-induced proliferation and differentiation of ex vivo human lung fibroblasts into myofibroblasts through <g>ERK</g>/<g>Akt</g> <u>inhibition </u>and <g>PTEN</g> restoration | ||
| 4 | +Up-regulation of heparan sulfate 6-O-sulfation in <d>idiopathic pulmonary fibrosis</d> | ||
| 5 | +Immunoglobulin A in serum: an old acquaintance as a new prognostic biomarker in <d>idiopathic pulmonary fibrosis</d> | ||
| 6 | +[Pulmonary fibrosis--a therapeutic dilemma?] | ||
| 7 | +<g>Syndecan-2</g> exerts antifibrotic effects by promoting <g>caveolin-1</g>-mediated transforming growth factor-b receptor I internalization and inhibiting transforming growth factor-b1 signaling | ||
| 8 | +Modulation of specific beta cell gene (re)expression during in vitro expansion of human pancreatic islet cells | ||
| 9 | +<r>Regulation </r>of human lung fibroblast <g>C1q</g>-receptors by <g>transforming growth factor-beta</g> and <g>tumor necrosis factor-alpha</g> | ||
| 10 | +Amplification of <g>TGFb</g> | ||
| 11 | +Comparison between conventional and "clinical" assessment of experimental lung <d>fibrosis</d> | ||
| 12 | +[<d>Idiopathic pulmonary fibrosis</d> and <d>lung cancer</d>] | ||
| 13 | +<g>Periostin</g> promotes <d>fibrosis</d> and predicts progression in patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 14 | +<g>CCN5</g> <v>overexpression </v>inhibits profibrotic phenotypes via the <g>PI3K</g>/Akt signaling pathway in lung fibroblasts isolated from patients with <d>idiopathic pulmonary fibrosis</d> and in an in vivo model of <d>lung fibrosis</d> | ||
| 15 | +Pirfenidone attenuates bleomycin-induced pulmonary fibrosis in mice by <r>regulating </r><g>Nrf2</g>/<g>Bach1</g> equilibrium | ||
| 16 | +<g>Extracellular superoxide dismutase</g> has a highly specific <l>localization </l>in <d>idiopathic pulmonary fibrosis</d>/<d>usual interstitial pneumonia</d> | ||
| 17 | +Signaling pathways in the epithelial origins of <d>pulmonary fibrosis</d> | ||
| 18 | +Overexpression of <d>squamous cell carcinoma</d> antigen in <d>idiopathic pulmonary fibrosis</d>: clinicopathological correlations | ||
| 19 | +High levels of <g>IL-6</g> and <g>IL-8</g> characterize early-on <d>idiopathic pulmonary fibrosis</d> acute exacerbations | ||
| 20 | +An ex vivo model to induce early <d>fibrosis</d>-like changes in human precision-cut lung slices | ||
| 21 | +Regulation of the effects of <g>TGF-beta 1</g> by activation of latent <g>TGF-beta 1</g> and differential <e>expression </e>of <g>TGF-beta receptors (T beta R-I and T beta R-II</g>) in <d>idiopathic pulmonary fibrosis</d> | ||
| 22 | +The role of halofuginone in fibrosis: more to be explored? Fibrosis, which can be defined as an abnormal or excessive accumulation of extracellular matrix (ECM), particularly fibrillar collagens, is a key driver of progressive organ dysfunction in many inflammatory and metabolic diseases, including idiopathic pulmonary fibrosis (IPF), cirrhosis, nephropathy, and oral submucous fibrosis (OSF) | ||
| 23 | +Genomewide RNA expression profiling in lung identifies distinct signatures in <d>idiopathic pulmonary arterial hypertension</d> and <d>secondary pulmonary hypertension</d> | ||
| 24 | +Establishment of the mouse model of acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
| 25 | +Dehydroepiandrosterone has strong antifibrotic effects and is decreased in <d>idiopathic pulmonary fibrosis</d> | ||
| 26 | +Peripheral depletion of NK cells and imbalance of the Treg/Th17 axis in <d>idiopathic pulmonary fibrosis</d> patients | ||
| 27 | +Developmental Reprogramming in Mesenchymal Stromal Cells of Human Subjects with <d>Idiopathic Pulmonary Fibrosis</d> | ||
| 28 | +Metformin <d>attenuates lung fibrosis</d> development via <g>NOX4</g> <u>suppression.</u> | ||
| 29 | +<g>Plasminogen activator inhibitor 1</g>, fibroblast apoptosis resistance, and aging-related susceptibility to lung <d>fibrosis</d> | ||
| 30 | +<u>Inhibition </u>of <g>HSP27</g> blocks <d>fibrosis</d> development and EMT features by promoting <g>Snail</g> degradation | ||
| 31 | +Cytokine gene polymorphisms and serum cytokine levels in patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 32 | +<g>miR-9-5p</g> suppresses pro-fibrogenic transformation of fibroblasts and prevents organ <d>fibrosis</d> by targeting <g>NOX4</g> and <g>TGFBR2</g> | ||
| 33 | +Raised serum levels of <g>IGFBP-1</g> and <g>IGFBP-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 34 | +Determining the True Selectivity Profile of av Integrin Ligands Using Radioligand Binding: Applying an Old Solution to a New Problem | ||
| 35 | +Signalling pathways from NADPH oxidase-4 to <d>idiopathic pulmonary fibrosis</d> | ||
| 36 | +<r>Effects </r>of a leukotriene B4 receptor antagonist on bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 37 | +Tumor <d>necrosis</d> factor superfamily 14 (<d>LIGHT</d>) controls <g>thymic stromal lymphopoietin</g> to drive <d>pulmonary fibrosis</d> | ||
| 38 | +<g>Pigment epithelium-derived factor</g> in <d>idiopathic pulmonary fibrosis</d>: a role in aberrant angiogenesis | ||
| 39 | +Profibrotic role of <g>WNT10A</g> via <g>TGF-b</g> signaling in <d>idiopathic pulmonary fibrosis</d> | ||
| 40 | +Activated human T lymphocytes inhibit <g>TGFb</g>-induced fibroblast to myofibroblast differentiation via prostaglandins D2 and E2 | ||
| 41 | +The Role of PPARs in Lung <d>Fibrosis</d> | ||
| 42 | +Methylation-mediated <g>BMPER</g> <e>expression </e>in fibroblast activation in vitro and lung <d>fibrosis</d> in mice in vivo | ||
| 43 | +<d>Fibrosis</d> of two: Epithelial cell-fibroblast interactions in <d>pulmonary fibrosis</d> | ||
| 44 | +Peptide-mediated inhibition of <g>mitogen-activated protein kinase-activated protein kinase-2</g> ameliorates bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 45 | +Free radical generation induces epithelial-to-mesenchymal transition in lung epithelium via a <g>TGF-b1</g>-dependent mechanism | ||
| 46 | +The potential application of strategic released apigenin from polymeric carrier in pulmonary fibrosis | ||
| 47 | +Role of integrin-<v>mediated </v><g>TGFbeta</g> <v>activation </v>in the pathogenesis of <d>pulmonary fibrosis</d> | ||
| 48 | +Novel pharmacological approaches to manage <d>interstitial lung fibrosis</d> in the twenty-first century | ||
| 49 | +Lipoxin A4 Attenuates Constitutive and <g>TGF-b1</g>-Dependent Profibrotic Activity in Human Lung Myofibroblasts | ||
| 50 | +<v>Overexpression </v>of <g>Sulf2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 51 | +Essential role for the <g>ATG4B</g> protease and autophagy in bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 52 | +Microarray profiling reveals <u>suppressed </u>interferon stimulated gene program in fibroblasts from scleroderma-associated <d>interstitial lung disease</d> | ||
| 53 | +<g>Bone morphogenetic protein-4</g> inhibitor <g>gremlin</g> is <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> | ||
| 54 | +<g>Hsp90</g> <r>regulation </r>of fibroblast activation in <d>pulmonary fibrosis</d> | ||
| 55 | +<g>Glucagon like peptide-1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d>, involving the <u>inactivation </u>of NF-kB in mice | ||
| 56 | +Smooth muscle alpha-actin <e>expression </e>and myofibroblast differentiation by <g>TGFbeta</g> are <v>dependent </v>upon <g>MK2</g> | ||
| 57 | +The K+ channel <g>KCa3.1</g> as a novel target for <d>idiopathic pulmonary fibrosis</d> | ||
| 58 | +<g>MiR-185</g>/<g>AKT</g> and <g>miR-29a</g>/collagen 1a pathways are <v>activated </v>in <d>IPF</d> | ||
| 59 | +Arsenic trioxide inhibits transforming growth factor-b1-induced <d>fibroblast to myofibroblast differentiation</d> in vitro and bleomycin induced lung <d>fibrosis</d> in vivo | ||
| 60 | +<g>Spiruchostatin A</g> inhibits proliferation and differentiation of fibroblasts from patients with <d>pulmonary fibrosis</d> | ||
| 61 | +<v>Elevated </v><g>sL1</g>-CAM levels in BALF and serum of <d>IPF</d> patients | ||
| 62 | +Lung myofibroblasts are characterized by <u>down-regulated </u><g>cyclooxygenase-2</g> and its main metabolite, prostaglandin E2 | ||
| 63 | +Cigarette Smoke Enhances the Expression of Profibrotic Molecules in Alveolar Epithelial Cells | ||
| 64 | +<g>Wilms' tumor 1</g> (<g>Wt1</g>) regulates pleural mesothelial cell plasticity and transition into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 65 | +<g>miR-26a</g> suppresses EMT by disrupting the <g>Lin28B</g>/<g>let-7d</g> axis: potential cross-talks among miRNAs in <d>IPF</d> | ||
| 66 | +microRNA-1343 attenuates pathways of <d>fibrosis</d> by targeting the <g>TGF-b</g> receptors | ||
| 67 | +Kinase <u>inhibitors </u>fail to induce mesenchymal-epithelial transition in fibroblasts from fibrotic lung tissue | ||
| 68 | +Microarray identifies ADAM family members as key responders to <g>TGF-beta1</g> in alveolar epithelial cells | ||
| 69 | +<g>Transgelin</g> is a direct target of <g>TGF-beta</g>/<g>Smad3</g>-dependent epithelial cell <d>migration in lung fibrosis</d> | ||
| 70 | +The mannose-6-phosphate analogue, PXS64, inhibits <d>fibrosis</d> via <g>TGF-b1</g> pathway in human lung fibroblasts | ||
| 71 | +<u>Reduced </u><e>expression </e>of <g>BMP3</g> contributes to the development of <d>pulmonary fibrosis</d> and predicts the unfavorable prognosis in IIP patients | ||
| 72 | +Role of <g>CD248</g> as a potential severity marker in <d>idiopathic pulmonary fibrosis</d> | ||
| 73 | +<g>IL-4</g> polymorphisms, HRCT score and lung tissue markers in <d>idiopathic pulmonary fibrosis</d> | ||
| 74 | +Early growth response transcription factors: key mediators of <d>fibrosis</d> and novel targets for anti-fibrotic therapy | ||
| 75 | +<g>Toll-like receptor 4</g> activation attenuates profibrotic response in control lung fibroblasts but not in fibroblasts from patients with <d>IPF</d> | ||
| 76 | +Titration of non-replicating adenovirus as a vector for <v>transducing </v>active <g>TGF-beta1</g> gene <e>expression </e>causing <d>inflammation</d> and fibrogenesis in the lungs of C57BL/6 mice | ||
| 77 | +Herpes <d>virus infection</d> is associated with vascular remodeling and <d>pulmonary hypertension</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 78 | +Effect of substrate stiffness on pulmonary fibroblast activation by <g>TGF-b</g> | ||
| 79 | +<g>BAX inhibitor-1</g>-associated <g>V-ATPase</g> glycosylation <v>enhances </v>collagen degradation in <d>pulmonary fibrosis</d> | ||
| 80 | +Sphingosine-1-phosphate lyase is an endogenous suppressor of <d>pulmonary fibrosis</d>: role of <g>S1P</g> signalling and autophagy | ||
| 81 | +<g>Nuclear factor erythroid 2-related factor 2</g> nuclear translocation induces <d>myofibroblastic dedifferentiation</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 82 | +<g>Matrix metalloproteinase (MMP)-19</g> <u>deficient </u>fibroblasts display a profibrotic phenotype | ||
| 83 | +A translational preclinical model of <d>interstitial pulmonary fibrosis</d> and <d>pulmonary hypertension</d>: mechanistic pathways driving disease pathophysiology | ||
| 84 | +Comparative study of transforming growth factor-b signalling and regulatory molecules in human and canine <d>idiopathic pulmonary fibrosis</d> | ||
| 85 | +A critical role for the <g>mTORC2</g> pathway in <d>lung fibrosis</d> | ||
| 86 | +Cytokine gene polymorphisms and BALF cytokine levels in <d>interstitial lung diseases</d> | ||
| 87 | +<g>PI3K</g> p110y <v>overexpression </v>in <d>idiopathic pulmonary fibrosis lung</d> tissue and fibroblast cells: in vitro effects of its inhibition | ||
| 88 | +Low-dose paclitaxel ameliorates <d>pulmonary fibrosis</d> by suppressing <g>TGF-b1</g>/<g>Smad3</g> pathway via <g>miR-140</g> upregulation | ||
| 89 | +MicroRNAs in <d>idiopathic pulmonary fibrosis</d> | ||
| 90 | +Two-Way Conversion between Lipogenic and Myogenic Fibroblastic Phenotypes Marks the Progression and Resolution of Lung <d>Fibrosis</d> | ||
| 91 | +Membrane type-matrix metalloproteinases in <d>idiopathic pulmonary fibrosis</d> | ||
| 92 | +<g>BARD1</g> mediates <g>TGF-b</g> signaling in <d>pulmonary fibrosis</d> | ||
| 93 | +Increased <d>alveolar</d> soluble <g>annexin V</g> promotes <d>lung inflammation</d> and <d>fibrosis</d> | ||
| 94 | +Autophagy in <d>idiopathic pulmonary fibrosis</d> | ||
| 95 | +Microencapsulation of lefty-secreting engineered cells for <d>pulmonary fibrosis</d> therapy in mice | ||
| 96 | +Bile acids induce activation of alveolar epithelial cells and lung fibroblasts through farnesoid X receptor-dependent and independent pathways | ||
| 97 | +<g>TGF-beta</g> driven lung <d>fibrosis</d> is macrophage dependent and blocked by Serum amyloid P | ||
| 98 | +<g>TGF-b1</g> <v>induces </v><g>Fstl1</g> via the <g>Smad3</g>-<g>c-Jun</g> pathway in lung fibroblasts | ||
| 99 | +Exercise <u>Reduces </u>Lung <d>Fibrosis</d> | ||
| 100 | +Genetic polymorphism in <g>matrix metalloproteinase-9</g> and <g>transforming growth factor-b1</g> and susceptibility to <d>combined pulmonary fibrosis</d> and <d>emphysema</d> in a Chinese population | ||
| 101 | +MS80, a novel sulfated oligosaccharide, inhibits <d>pulmonary fibrosis</d> by targeting <g>TGF-beta1</g> both in vitro and in vivo | ||
| 102 | +Protective role of gambogic acid in experimental <d>pulmonary fibrosis</d> in vitro and in vivo | ||
| 103 | +Sputum biomarkers in <d>IPF</d>: Evidence for raised gene <e>expression </e>and protein level of <g>IGFBP-2</g>, <g>IL-8</g> and <g>MMP-7</g> | ||
| 104 | +Sorafenib ameliorates bleomycin-induced <d>pulmonary fibrosis</d>: potential roles in the inhibition of epithelial-mesenchymal transition and fibroblast activation | ||
| 105 | +<g>Forkhead Box F1</g> (<g>FOXF1</g>) <u>represses </u>cell growth, COL1 and <g>ARPC2</g> <e>expression </e>in lung fibroblasts in vitro | ||
| 106 | +[Different cytokine profiles in <d>usual interstitial pneumonia</d> and <d>nonspecific interstitial pneumonia</d>] | ||
| 107 | +Targeting of <g>Discoidin Domain Receptor 2</g> (<g>DDR2</g>) Prevents Myofibroblast Activation and Neovessel Formation During <d>Pulmonary Fibrosis</d> | ||
| 108 | +<g>MicroRNA-29c</g> regulates apoptosis sensitivity via modulation of the cell-surface death receptor, Fas, in lung fibroblasts | ||
| 109 | +Simvastatin attenuates <g>TGF-b1</g>-induced epithelial-mesenchymal transition in human alveolar epithelial cells | ||
| 110 | +Expression of <g>suppressor of cytokine signaling 1</g> in the peripheral blood of patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 111 | +<g>Prostaglandin F(2alpha) receptor</g> signaling facilitates bleomycin-induced <d>pulmonary fibrosis</d> independently of transforming growth factor-beta | ||
| 112 | +Profibrotic role of <g>miR-154</g> in <d>pulmonary fibrosis</d> | ||
| 113 | +Role of <g>protease-activated receptor-2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 114 | +<e>Expression </e>of mucosa-related integrin alphaEbeta7 on <d>alveolar T</d> cells in <d>interstitial lung diseases</d> | ||
| 115 | +Anchorage-independent colony growth of pulmonary fibroblasts derived from fibrotic human lung tissue | ||
| 116 | +Cytoskeletal protein modulation in <d>pulmonary alveolar myofibroblasts</d> during <d>idiopathic pulmonary fibrosis</d> | ||
| 117 | +<g>Aortic carboxypeptidase-like protein</g> (<g>ACLP</g>) enhances lung myofibroblast differentiation through transforming growth factor b receptor-dependent and -independent pathways | ||
| 118 | +The latent form of <g>TGFbeta(1)</g> is induced by <g>TNFalpha</g> through an <g>ERK</g> specific pathway and is <v>activated </v>by asbestos-derived reactive oxygen species in vitro and in vivo | ||
| 119 | +<g>Transglutaminase 2</g> and its role in <d>pulmonary fibrosis</d> | ||
| 120 | +Differential effects of human neutrophil peptide-1 on growth factor and <g>interleukin-8</g> production by human lung fibroblasts and epithelial cells | ||
| 121 | +Sunitinib, a Small-Molecule Kinase <u>Inhibitor,</u> | ||
| 122 | +Fibroblasts from <d>idiopathic pulmonary fibrosis</d> and normal lungs differ in growth rate, apoptosis, and tissue <u>inhibitor </u>of metalloproteinases <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>chronic lung disorder</d> characterized by fibroblast proliferation and extracellular matrix accumulation | ||
| 123 | +Transforming growth factor-b1 downregulates <g>vascular endothelial growth factor</g>-D expression in human lung fibroblasts via the <g>Jun NH2-terminal kinase</g> signaling pathway | ||
| 124 | +<g>Ubiquitin carboxyl-terminal hydrolase-L5</g> promotes <g>TGFb-1</g> signaling by de-ubiquitinating and stabilizing <g>Smad2</g>/<g>Smad3</g> in <d>pulmonary fibrosis</d> | ||
| 125 | +<g>Chop</g> | ||
| 126 | +<g>Focal adhesion kinase</g> signaling determines the fate of lung epithelial cells in response to <g>TGF-b</g> | ||
| 127 | +Effects of particulate matter from straw burning on <d>lung fibrosis</d> in mice | ||
| 128 | +<g>miR -221</g> targets <g>HMGA2</g> to inhibit bleomycin -induced <d>pulmonary fibrosis</d> by regulating <g>TGF -b1</g>/<g>Smad3</g>-induced EMT | ||
| 129 | +<g>VCAM-1</g> is a <g>TGF-b1</g> inducible gene <v>upregulated </v>in <d>idiopathic pulmonary fibrosis</d> | ||
| 130 | +<g>EZH2</g> enhances the differentiation of fibroblasts into myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 131 | +<u>Suppression </u>of <g>plasminogen activator inhibitor-1</g> by RNA interference attenuates <d>pulmonary fibrosis</d> | ||
| 132 | +Effect of pirfenidone on proliferation, <g>TGF-b</g>-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts | ||
| 133 | +<g>WISP1</g> mediates <g>IL-6</g>-dependent proliferation in primary human lung fibroblasts | ||
| 134 | +<d>Idiopathic pulmonary fibrosis</d>: immunohistochemical analysis provides fresh insights into lung tissue remodelling with implications for novel prognostic markers | ||
| 135 | +Amplified canonical transforming growth factor-b signalling<i>via</i><d>heat shock</d> protein 90 in <d>pulmonary fibrosis</d> | ||
| 136 | +[Quantifying plasma levels of <g>transforming growth factor beta1</g> in <d>idiopathic pulmonary fibrosis</d>] | ||
| 137 | +The matricellular protein <g>CCN1</g> enhances <g>TGF-b1</g>/<g>SMAD3</g>-dependent profibrotic signaling in fibroblasts and contributes to fibrogenic responses to <d>lung injury</d> | ||
| 138 | +Tubastatin ameliorates <d>pulmonary fibrosis</d> by targeting the TGFb-PI3K-<g>Akt</g> pathway | ||
| 139 | +<v>Upregulation </v>of alveolar <e>levels </e>of activin B, but not activin A, in lungs of west highland white terriers with <d>idiopathic pulmonary fibrosis</d> and <d>diffuse alveolar damage</d> | ||
| 140 | +Absence of <g>Thy-1</g> results in <g>TGF-b</g> induced <g>MMP-9</g> expression and confers a profibrotic phenotype to human lung fibroblasts | ||
| 141 | +Lung fibrotic <g>tenascin-C</g> <v>upregulation </v>is associated with other extracellular matrix proteins and <v>induced </v>by TGFb1 | ||
| 142 | +Tannic acid attenuates TGF-b1-induced epithelial-to-mesenchymal transition by effectively intervening TGF-b signaling in lung epithelial cells | ||
| 143 | +Shikonin suppresses pulmonary fibroblasts proliferation and activation by <r>regulating </r><g>Akt</g> and <g>p38</g> | ||
| 144 | +Abrogation of <g>TGF-beta1</g>-induced fibroblast-myofibroblast differentiation by <g>histone deacetylase</g> <u>inhibition.</u> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a devastating disease with no known effective pharmacological therapy | ||
| 145 | +<g>JAK2</g> mediates <d>lung fibrosis</d>, <d>pulmonary vascular remodelling</d> and <d>hypertension</d> in <d>idiopathic pulmonary fibrosis</d>: an experimental study | ||
| 146 | +<g>AKT2</g> | ||
| 147 | +Regulation of myofibroblast differentiation by <g>miR-424</g> during epithelial-to-mesenchymal transition | ||
| 148 | +Bleomycin in the setting of <d>lung fibrosis</d> induction: From biological mechanisms to counteractions | ||
| 149 | +MicroRNA-101 attenuates pulmonary fibrosis by inhibiting fibroblast proliferation and activation | ||
| 150 | +<g>Extracellular Matrix Metalloproteinase Inducer</g> (<g>EMMPRIN</g>) promotes lung fibroblast proliferation, survival and differentiation to myofibroblasts | ||
| 151 | +<g>TRPV4</g> mediates myofibroblast differentiation and <d>pulmonary fibrosis</d> in mice | ||
| 152 | +Modulation of <g>CD11c</g>+ lung dendritic cells in respect to <g>TGF-b</g> in experimental <d>pulmonary fibrosis</d> | ||
| 153 | +Melatonin attenuates <g>TGFb1</g>-induced epithelial-mesenchymal transition in lung alveolar epithelial cells | ||
| 154 | +Long-acting human serum albumin-thioredoxin fusion protein suppresses bleomycin-induced <d>pulmonary fibrosis progression</d> | ||
| 155 | +Fibrogenic Lung Injury Induces Non-Cell-Autonomous Fibroblast Invasion | ||
| 156 | +<g>TGF-b</g> activation and lung <d>fibrosis</d> | ||
| 157 | +Induction of epithelial-mesenchymal transition in alveolar epithelial cells by <g>transforming growth factor-beta1</g>: potential role in <d>idiopathic pulmonary fibrosis</d> | ||
| 158 | +<r>Deregulation </r>of selective autophagy during aging and <d>pulmonary fibrosis</d>: the role of <g>TGFb1</g> | ||
| 159 | +<v>Increased </v>interleukin-1 receptor antagonist in <d>idiopathic pulmonary fibrosis</d> | ||
| 160 | +Recent advances in molecular targets and treatment of <d>idiopathic pulmonary fibrosis</d>: focus on <g>TGFbeta</g> signaling and the myofibroblast | ||
| 161 | +<g>TIAM1</g> inhibits lung fibroblast differentiation in <d>pulmonary fibrosis</d> | ||
| 162 | +Targeting <g>sphingosine kinase 1</g> attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 163 | +Re-evaluation of fibrogenic cytokines in <d>lung fibrosis</d> | ||
| 164 | +Targeting genes for treatment in <d>idiopathic pulmonary fibrosis</d>: challenges and opportunities, promises and pitfalls | ||
| 165 | +Defect of pro-<g>hepatocyte growth factor</g> activation by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 166 | +Epithelial Cell Mitochondrial Dysfunction and <g>PINK1</g> | ||
| 167 | +<g>Bone morphogenetic protein</g>-inducer tilorone identified by high-throughput screening is antifibrotic in vivo | ||
| 168 | +Pleural mesothelial cell differentiation and invasion in <d>fibrogenic lung injury</d> | ||
| 169 | +<l>Release </l>of biologically active <g>TGF-beta1</g> by alveolar epithelial cells results in <d>pulmonary fibrosis</d> | ||
| 170 | +<g>IL-17A</g> deficiency mitigates bleomycin-induced complement activation during <d>lung fibrosis</d> | ||
| 171 | +IPF lung fibroblasts have a senescent phenotype | ||
| 172 | +<g>RhoA</g> signaling <r>modulates </r><g>cyclin D1</g> <e>expression </e>in human lung fibroblasts; implications for <d>idiopathic pulmonary fibrosis</d> | ||
| 173 | +Studies of <g>hepatocyte growth factor</g> in bronchoalveolar lavage fluid in chronic <d>interstitial lung diseases</d> | ||
| 174 | +Autophagy and <d>inflammation</d> in chronic <d>respiratory disease</d> | ||
| 175 | +Inhibitory effect of <g>receptor for advanced glycation end products</g> (<g>RAGE</g>) on the <g>TGF-b</g>-induced alveolar epithelial to mesenchymal transition | ||
| 176 | +Cytokine gene polymorphisms in <d>idiopathic pulmonary fibrosis</d> | ||
| 177 | +The profibrotic cytokine <g>transforming growth factor-b1</g> increases endothelial progenitor cell angiogenic properties | ||
| 178 | +<g>Cub domain containing protein 1</g> (<g>CDCP1</g>) negatively regulates TGFb signaling and myofibroblast differentiation | ||
| 179 | +Regulation of transforming growth factor-b1-driven lung <d>fibrosis</d> by <g>galectin-3</g> | ||
| 180 | +<e>Effects </e>of the <d>tumor</d> suppressor <g>PTEN</g> on the pathogenesis of <d>idiopathic pulmonary fibrosis</d> in Chinese patients | ||
| 181 | +Increased levels of prostaglandin E-major urinary metabolite (PGE-MUM) in chronic fibrosing <d>interstitial pneumonia</d> | ||
| 182 | +Epigenetic <r>Regulation </r>of <g>Caveolin-1</g> | ||
| 183 | +Mechanisms of <d>fibrosis</d> in <d>coal workers' pneumoconiosis</d> | ||
| 184 | +Expression of <g>150-kDa oxygen-regulated protein</g> (<g>ORP150</g>) stimulates bleomycin-induced <d>pulmonary fibrosis and dysfunction</d> in mice | ||
| 185 | +Different effects of growth factors on proliferation and matrix production of normal and fibrotic human lung fibroblasts | ||
| 186 | +Role of endoplasmic reticulum stress in age-related susceptibility to lung <d>fibrosis</d> | ||
| 187 | +Are mast cells instrumental for <d>fibrotic diseases</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a <d>fatal lung disorder</d> of unknown etiology characterized by accumulation of lung fibroblasts and extracellular matrix deposition, ultimately leading to compromised tissue architecture and lung function capacity | ||
| 188 | +Alveolar epithelial cell injury with Epstein-Barr virus <v>upregulates </v><g>TGFbeta1</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a refractory and lethal <d>interstitial lung disease</d> characterized by alveolar epithelial cells apoptosis, fibroblast proliferation, and ECM protein deposition | ||
| 189 | +<d>Pulmonary fibrosis</d>: pathogenesis, etiology and regulation | ||
| 190 | +Activated MCTC mast cells infiltrate diseased lung areas in <d>cystic fibrosis</d> and <d>idiopathic pulmonary fibrosis</d> | ||
| 191 | +<g>miR</g>-323a-3p regulates <d>lung fibrosis</d> by targeting multiple profibrotic pathways | ||
| 192 | +<g>PPAR</g>-y ligands repress <g>TGFb</g>-induced myofibroblast differentiation by targeting the <g>PI3K</g>/<g>Akt</g> pathway: implications for therapy of <d>fibrosis</d> | ||
| 193 | +<g>TGF-b1</g> <v>stimulates </v><g>HDAC4</g> nucleus-to-cytoplasm <l>translocation </l>and <g>NADPH oxidase 4</g>-derived reactive oxygen species in normal human lung fibroblasts | ||
| 194 | +Effects of <d>cigarette smoke extract</d> on A549 cells and human lung fibroblasts treated with <g>transforming growth factor-beta1</g> in a coculture system | ||
| 195 | +De-ubiquitinating enzyme, <g>USP11</g>, promotes <g>transforming growth factor b-1</g> signaling through stabilization of transforming growth factor b receptor II | ||
| 196 | +Single-cell RNA sequencing identifies diverse roles of epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
| 197 | +The antifibrotic effects and mechanisms of microRNA-26a action in <d>idiopathic pulmonary fibrosis</d> | ||
| 198 | +Phosphatase and tensin homolog deleted on chromosome 10 contributes to phenotype transformation of fibroblasts in <d>idiopathic pulmonary fibrosis</d> via multiple pathways | ||
| 199 | +Lower expression of platelet derived growth factor is associated with better overall survival rate of patients with idiopathic nonspecific interstitial pneumonia | ||
| 200 | +Triptolide suppresses paraquat induced <d>idiopathic pulmonary fibrosis</d> by inhibiting <g>TGFB1</g>-dependent epithelial mesenchymal transition | ||
| 201 | +MicroRNA-326 regulates profibrotic functions of transforming growth factor-b in <d>pulmonary fibrosis</d> | ||
| 202 | +<g>Endothelin-1</g> <v>induces </v>alveolar epithelial-mesenchymal transition through endothelin type A receptor-<v>mediated </v><e>production </e>of <g>TGF-beta1</g> | ||
| 203 | +Investigation of bone marrow mesenchymal stem cells (BM MSCs) involvement in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) | ||
| 204 | +<g>Neutrophil elastase</g> promotes myofibroblast <d>differentiation in lung fibrosis</d> | ||
| 205 | +<g>MAP3K19</g> | ||
| 206 | +Differential mRNA expression of <g>insulin-like growth factor-1</g> splice variants in patients with <d>idiopathic pulmonary fibrosis</d> and <d>pulmonary sarcoidosis</d> | ||
| 207 | +<g>p63</g> - Key molecule in the early phase of <d>epithelial abnormality</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 208 | +Effect of Renshen Pingfei Decoction, a traditional Chinese prescription, on <d>IPF</d> <v>induced </v>by Bleomycin in rats and <r>regulation </r>of <g>TGF-b1</g>/<g>Smad3</g> | ||
| 209 | +Pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
| 210 | +Macrophage <g>Bone Morphogenic Protein Receptor 2</g> (<g>BMPR2</g>) <u>depletion </u>in <d>Idiopathic Pulmonary Fibrosis</d> (<d>IPF</d>) and Group III Pulmonary <d>Hypertension</d> | ||
| 211 | +<u>Reduced </u><g>Ets Domain-containing Protein Elk1</g> | ||
| 212 | +Nitric oxide attenuates epithelial-mesenchymal transition in alveolar epithelial cells | ||
| 213 | +<g>HSP27</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation through the <g>Smad3</g> and <g>ERK</g> pathways | ||
| 214 | +<g>Cartilage oligomeric matrix protein</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 215 | +Negative regulation of myofibroblast differentiation by <g>PTEN</g> (Phosphatase and Tensin Homolog Deleted on chromosome 10) | ||
| 216 | +Data on <g>CUX1</g> isoforms in <d>idiopathic pulmonary fibrosis lung</d> and <d>systemic sclerosis</d> skin tissue sections | ||
| 217 | +Alveolar epithelial cells express mesenchymal proteins in patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 218 | +<e>Expression </e>of <g>WNT5A</g> in <d>Idiopathic Pulmonary Fibrosis</d> and Its <r>Control </r>by <g>TGF-b</g> and <g>WNT7B</g> in Human Lung Fibroblasts | ||
| 219 | +<d>Idiopathic Pulmonary Fibrosis</d>: Aging, Mitochondrial Dysfunction, and Cellular Bioenergetics | ||
| 220 | +<g>SPARC</g> suppresses apoptosis of <d>idiopathic pulmonary fibrosis</d> fibroblasts through constitutive <v>activation </v>of <g>beta-catenin</g> | ||
| 221 | +Resveratrol-Mediated Repression and Reversion of Prostatic Myofibroblast Phenoconversion | ||
| 222 | +[The potential role of cytokines expression in <d>idiopathic pulmonary fibrosis</d>] | ||
| 223 | +Effect of an immunotoxin to <g>folate receptor beta</g> on bleomycin-induced <d>experimental pulmonary fibrosis</d> | ||
| 224 | +The hedgehog system machinery controls transforming growth factor-b-dependent myofibroblastic differentiation in humans: involvement in <d>idiopathic pulmonary fibrosis</d> | ||
| 225 | +<v>Elevated </v><e>expression </e>of <g>NEU1</g> sialidase in <d>idiopathic pulmonary fibrosis</d> <v>provokes </v>pulmonary collagen deposition, <d>lymphocytosis</d>, and <d>fibrosis</d> | ||
| 226 | +Genetic partitioning of <g>interleukin-6</g> signalling in mice dissociates <g>Stat3</g> from <g>Smad3</g>-mediated <d>lung fibrosis</d> | ||
| 227 | +Reactive oxygen species are required for maintenance and differentiation of primary lung fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 228 | +<v>Upregulation </v>of <g>activin</g>-B and <g>follistatin</g> in <d>pulmonary fibrosis</d> - a translational study using human biopsies and a specific inhibitor in mouse <d>fibrosis</d> models | ||
| 229 | +Oxidant-antioxidant imbalance as a potential contributor to the progression of human <d>pulmonary fibrosis</d> | ||
| 230 | +Increased production and immunohistochemical localization of <g>transforming growth factor-beta</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 231 | +<u>Inhibition </u>of the <g>KCa3.1</g> | ||
| 232 | +<g>FGF-1</g> reverts epithelial-mesenchymal transition induced by <g>TGF-{beta}1</g> through MAPK/ERK kinase pathway | ||
| 233 | +N-acetylcysteine inhibits alveolar epithelial-mesenchymal transition | ||
| 234 | +Type V collagen induced tolerance suppresses collagen deposition, <g>TGF-b</g> and associated transcripts in <d>pulmonary fibrosis</d> | ||
| 235 | +Type II alveolar epithelial cells and interstitial fibroblasts express <g>connective tissue growth factor</g> in <d>IPF</d> | ||
| 236 | +<g>CUX1</g>/Wnt signaling regulates epithelial mesenchymal transition in EBV infected epithelial cells | ||
| 237 | +Lactic acid is elevated in <d>idiopathic pulmonary fibrosis</d> and induces myofibroblast differentiation via pH-dependent activation of transforming growth factor-b | ||
| 238 | +Preventive and therapeutic effects of thymosin b4 N-terminal fragment Ac-SDKP in the bleomycin model of pulmonary fibrosis | ||
| 239 | +Epithelial cell alpha3beta1 integrin links <g>beta-catenin</g> and Smad signaling to promote myofibroblast formation and <d>pulmonary fibrosis</d> | ||
| 240 | +EMT and <d>interstitial lung disease</d>: a mysterious relationship | ||
| 241 | +Pirfenidone exerts antifibrotic effects through <u>inhibition </u>of GLI transcription factors | ||
| 242 | +<g>STAT3</g>-mediated signaling dysregulates lung fibroblast-myofibroblast activation and differentiation in UIP/IPF | ||
| 243 | +Epithelial stem cell exhaustion in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
| 244 | +FAK-related nonkinase is a multifunctional negative regulator of <d>pulmonary fibrosis</d> | ||
| 245 | +Nitrated fatty acids reverse <d>pulmonary fibrosis</d> by dedifferentiating myofibroblasts and promoting collagen uptake by alveolar macrophages | ||
| 246 | +Berberine attenuates bleomycin induced <d>pulmonary toxicity</d> and <d>fibrosis</d> via <u>suppressing </u><g>NF-kB</g> dependant <g>TGF-b</g> <v>activation:</v> a biphasic experimental study | ||
| 247 | +<g>N-acetyl-L-cysteine</g> inhibits <g>TGF-beta1</g>-induced profibrotic responses in fibroblasts | ||
| 248 | +Interleukin-17 induces human alveolar epithelial to mesenchymal cell transition via the <g>TGF-b1</g> <v>mediated </v><g>Smad2/3</g> and <g>ERK1/2</g> <v>activation.</v> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic and usually progressive <d>lung disease</d> and the epithelial-mesenchymal transition (EMT) may play an important role in the pathogenesis of <d>pulmonary fibrosis</d> | ||
| 249 | +<g>Transforming growth factor b1</g> (<g>TGFb1</g>)-induced CD44V6-<g>NOX4</g> signaling in pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
| 250 | +<g>TGF-beta1</g> induces human alveolar epithelial to mesenchymal cell transition (EMT) | ||
| 251 | +Thalidomide prevents bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
| 252 | +Identification and validation of differentially expressed transcripts by RNA-sequencing of formalin-fixed, paraffin-embedded (FFPE) lung tissue from patients with Idiopathic Pulmonary Fibrosis | ||
| 253 | +Intratracheal bleomycin causes airway remodeling and airflow obstruction in mice | ||
| 254 | +Significance of <v>elevated </v>procollagen-III-peptide and <g>transforming growth factor-beta</g> levels of bronchoalveolar lavage fluids from <d>idiopathic pulmonary fibrosis</d> patients | ||
| 255 | +<g>MiR-338</g>* targeting <g>smoothened</g> to inhibit <d>pulmonary fibrosis</d> by epithelial-mesenchymal transition | ||
| 256 | +Proteasomal regulation of <d>pulmonary fibrosis</d> | ||
| 257 | +Pleural mesothelial cells in <d>pleural and lung diseases</d> | ||
| 258 | +<d>Idiopathic pulmonary fibrosis</d>: an altered fibroblast proliferation linked to <d>cancer</d> biology | ||
| 259 | +Current and novel drug therapies for <d>idiopathic pulmonary fibrosis</d> | ||
| 260 | +Epithelium-specific deletion of <g>TGF-b</g> receptor type II protects mice from bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 261 | +<g>Caveolin-1</g>: a critical regulator of <d>lung fibrosis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 262 | +<g>Renin</g> is an angiotensin-independent profibrotic mediator: role in <d>pulmonary fibrosis</d> | ||
| 263 | +<g>Protease activated receptor-1</g> regulates macrophage-mediated cellular senescence: a risk for <d>idiopathic pulmonary fibrosis</d> | ||
| 264 | +Role for alpha3 integrin in EMT and <d>pulmonary fibrosis</d> | ||
| 265 | +Beyond <g>TGFb</g> - Novel ways to target airway and parenchymal <d>fibrosis</d> | ||
| 266 | +<g>Cthrc1</g> lowers pulmonary collagen associated with bleomycin-induced <d>fibrosis</d> and protects lung function | ||
| 267 | +Wnt coreceptor <g>Lrp5</g> is a driver of <d>idiopathic pulmonary fibrosis</d> | ||
| 268 | +<g>Lysocardiolipin acyltransferase</g> regulates <g>TGF-b</g> mediated lung fibroblast differentiation | ||
| 269 | +Cytokine profiles in <d>idiopathic pulmonary fibrosis</d> suggest an important role for <g>TGF-beta</g> and <g>IL-10</g> | ||
| 270 | +Protective Effect of Ginsenoside Rg1 on Bleomycin-Induced Pulmonary Fibrosis in Rats: Involvement of <g>Caveolin-1</g> and <g>TGF-b1</g> | ||
| 271 | +The <g>JAK2</g> pathway is activated in <d>idiopathic pulmonary fibrosis</d> | ||
| 272 | +<g>CXCL9</g> | ||
| 273 | +Differing Expression of Cytokines and <d>Tumor</d> | ||
| 274 | +Sphingolipids in <d>pulmonary fibrosis</d> | ||
| 275 | +Sphingosine-1-phosphate is increased in patients with <d>idiopathic pulmonary fibrosis</d> and mediates epithelial to mesenchymal transition | ||
| 276 | +<g>miR-31</g> is a negative regulator of fibrogenesis and <d>pulmonary fibrosis</d> | ||
| 277 | +<u>Defect </u>of <g>hepatocyte growth factor</g> <l>secretion </l>by fibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 278 | +<g>MiR-5100</g> targets <g>TOB2</g> to drive epithelial-mesenchymal transition associated with <v>activating </v><g>smad2/3</g> in lung epithelial cells | ||
| 279 | +The impact of <g>TGF-b</g> on lung <d>fibrosis</d>: from targeting to biomarkers | ||
| 280 | +Mast cell chymase: an indispensable instrument in the pathological symphony of <d>idiopathic pulmonary fibrosis</d>? <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic, progressive and fatal <d>lung disease</d> with no known etiology and treatment options | ||
| 281 | +Leucine-rich a-2 glycoprotein promotes <d>lung fibrosis</d> by modulating <g>TGF-b</g> signaling in fibroblasts | ||
| 282 | +<g>NOX4</g>/NADPH oxidase <e>expression </e>is <v>increased </v>in pulmonary fibroblasts from patients with <d>idiopathic pulmonary fibrosis</d> and mediates <g>TGFbeta1</g>-induced fibroblast differentiation into myofibroblasts | ||
| 283 | +Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts | ||
| 284 | +Normal Human Lung Epithelial Cells Inhibit Transforming Growth Factor-b Induced Myofibroblast Differentiation via Prostaglandin E2 | ||
| 285 | +Matrix regulation of <d>idiopathic pulmonary fibrosis</d>: the role of enzymes | ||
| 286 | +Carbon monoxide-bound hemoglobin-vesicles for the treatment of bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 287 | +Sustained <g>PI3K</g> | ||
| 288 | +Pirfenidone for the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
| 289 | +miR-18a-5p <u>Inhibits </u>Sub-pleural Pulmonary Fibrosis by Targeting <g>TGF-b</g> | ||
| 290 | +Pirfenidone <u>inhibits </u>the <e>expression </e>of <g>HSP47</g> in <g>TGF-beta1</g>-stimulated human lung fibroblasts | ||
| 291 | +Tissue inhibitor of metalloproteinase-3 is up-regulated by <g>transforming growth factor-beta1</g> in vitro and expressed in fibroblastic foci in vivo in <d>idiopathic pulmonary fibrosis</d> | ||
| 292 | +N-acetylcysteine <u>inhibits </u><g>TNF-alpha</g>, sTNFR, and <g>TGF-beta1</g> release by alveolar macrophages in <d>idiopathic pulmonary fibrosis</d> in vitro | ||
| 293 | +Increased Galectin-9 Concentration and Number of CD4+Foxp3high+Cells in Bronchoalveolar Lavage Fluid of Patients with <d>Cryptogenic Organizing Pneumonia</d> | ||
| 294 | +Rapamycin <v>increases </v><g>CCN2</g> <e>expression </e>of lung fibroblasts via <g>phosphoinositide 3-kinase</g> | ||
| 295 | +Transforming growth factor-b <u>inhibits </u>IQ motif containing guanosine triphosphatase <v>activating </v>protein 1 <e>expression </e>in lung fibroblasts via the nuclear factor-kB signaling pathway | ||
| 296 | +[The expressions and meanings of <g>BMP-7</g> and <g>TGF-b</g> in <d>idiopathic pulmonary fibrosis</d> and <d>idiopathic nonspecific interstitial pneumonia</d>] | ||
| 297 | +<g>Yin yang 1</g> is a novel regulator of <d>pulmonary fibrosis</d> | ||
| 298 | +Role of <d>von Hippel-Lindau</d> protein in fibroblast proliferation and <d>fibrosis</d> | ||
| 299 | +<g>X-linked inhibitor of apoptosis</g> regulates lung fibroblast resistance to Fas-mediated apoptosis | ||
| 300 | +<d>Idiopathic pulmonary fibrosis</d>: pathobiology of novel approaches to treatment | ||
| 301 | +Age-driven developmental drift in the pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
| 302 | +Endogenous <g>Semaphorin-7A</g> | ||
| 303 | +Progressive transforming growth factor beta1-induced <d>lung fibrosis</d> is blocked by an orally active <g>ALK5</g> kinase <u>inhibitor.</u> <d>Pulmonary fibrosis</d> is characterized by chronic scar formation and deposition of extracellular matrix, resulting in <d>impaired lung function</d> and <d>respiratory failure</d> | ||
| 304 | +Human lung myofibroblast <g>TGFb1</g>-dependent <g>Smad2/3</g> signalling is Ca(2+)-dependent and <r>regulated </r>by <g>KCa3.1</g> | ||
| 305 | +Simvastatin inhibits growth factor expression and modulates profibrogenic markers in lung fibroblasts | ||
| 306 | +The anti-fibrotic effect of <u>inhibition </u>of <g>TGFb</g>-<g>ALK5</g> signalling in experimental <d>pulmonary fibrosis</d> in mice is attenuated in the presence of concurrent y-herpesvirus infection | ||
| 307 | +MicroRNA regulatory networks in <d>idiopathic pulmonary fibrosis</d> | ||
| 308 | +Fibroblastic foci, covered with <d>alveolar epithelia</d> exhibiting <d>epithelial-mesenchymal transition</d>, destroy <d>alveolar septa</d> by disrupting blood flow in <d>idiopathic pulmonary fibrosis</d> | ||
| 309 | +[A role for mesothelial cells in the genesis of <d>idiopathic pulmonary fibrosis</d>?] | ||
| 310 | +<e>Overproduction </e>of collagen and <u>diminished </u><g>SOCS1</g> <e>expression </e>are causally linked in fibroblasts from <d>idiopathic pulmonary fibrosis</d> | ||
| 311 | +Antifibrotic effects of <g>cyclosporine A</g> on <g>TGF-b1</g>-treated lung fibroblasts and lungs from bleomycin-treated mice: role of <g>hypoxia-inducible factor-1a</g> | ||
| 312 | +<g>TGF-beta 1</g> as an enhancer of Fas-mediated apoptosis of lung epithelial cells | ||
| 313 | +<r>Regulation </r>of 26S Proteasome Activity in <d>Pulmonary Fibrosis</d> | ||
| 314 | +Therapeutic targets in fibrotic pathways | ||
| 315 | +Compromised peroxisomes in <d>idiopathic pulmonary fibrosis</d>, a vicious cycle inducing a higher fibrotic response via <g>TGF-b</g> signaling | ||
| 316 | +<d>Lung infection</d> with gamma-herpesvirus induces progressive <d>pulmonary fibrosis</d> in Th2-biased mice | ||
| 317 | +Mode of action of nintedanib in the treatment of <d>idiopathic pulmonary fibrosis</d> | ||
| 318 | +<g>Semaphorin 7a</g>+ regulatory T cells are associated with progressive <d>idiopathic pulmonary fibrosis</d> and are implicated in transforming growth factor-b1-induced <d>pulmonary fibrosis</d> | ||
| 319 | +Mesenchymal Stem Cells Correct Inappropriate Epithelial-mesenchyme Relation in <d>Pulmonary Fibrosis</d> | ||
| 320 | +Increased expression of 5-hydroxytryptamine2A/B receptors in <d>idiopathic pulmonary fibrosis</d>: a rationale for therapeutic intervention | ||
| 321 | +Angiotensin-<g>TGF-beta</g> 1 crosstalk in human <d>idiopathic pulmonary fibrosis</d>: autocrine mechanisms in myofibroblasts and macrophages | ||
| 322 | +<v>Increased </v>deposition of chondroitin/dermatan sulfate glycosaminoglycan and <v>upregulation </v>of b1,3-glucuronosyltransferase I in <d>pulmonary fibrosis</d> | ||
| 323 | +SNAI transcription factors mediate epithelial-mesenchymal transition in <d>lung fibrosis</d> | ||
| 324 | +Proliferation of pulmonary interstitial fibroblasts is mediated by <g>transforming growth factor-beta1</g>-induced release of extracellular <g>fibroblast growth factor-2</g> and <p>phosphorylation </p>of <g>p38</g> | ||
| 325 | +Pathogenesis pathways of <d>idiopathic pulmonary fibrosis</d> in bleomycin-induced <d>lung injury</d> model in mice | ||
| 326 | +Latent cytomegalovirus infection exacerbates experimental <d>pulmonary fibrosis</d> by <v>activating </v><g>TGF-b1</g> | ||
| 327 | +Prognostic factors for <d>idiopathic pulmonary fibrosis</d>: clinical, physiologic, pathologic, and molecular aspects | ||
| 328 | +<r>Effects </r>of antifibrotic agents on <g>TGF-beta1</g>, <g>CTGF</g> and <g>IFN-gamma</g> <e>expression </e>in patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 329 | +Hydrogen peroxide is a diffusible paracrine signal for the induction of epithelial cell death by activated myofibroblasts | ||
| 330 | +<g>Microsomal prostaglandin E synthase-1</g> <u>deficiency </u>exacerbates <d>pulmonary fibrosis</d> induced by bleomycin in mice | ||
| 331 | +<g>Secreted protein acidic and rich in cysteine</g> (<g>SPARC</g>) is upregulated by transforming growth factor (TGF)-b and is required for <g>TGF-b</g>-induced hydrogen peroxide production in fibroblasts | ||
| 332 | +Inhibition of NF-kappaB signaling reduces virus load and gammaherpesvirus-induced <d>pulmonary fibrosis</d> | ||
| 333 | +Effects and mechanisms of pirfenidone, prednisone and acetylcysteine on <d>pulmonary fibrosis</d> in rat <d>idiopathic pulmonary fibrosis</d> models | ||
| 334 | +<g>MiR-338</g>* suppresses fibrotic pathogenesis in <d>pulmonary fibrosis</d> through targeting <g>LPA1</g> | ||
| 335 | +Accelerated epithelial cell senescence in <d>IPF</d> and the inhibitory role of <g>SIRT6</g> in <g>TGF-b</g>-induced senescence of human bronchial epithelial cells | ||
| 336 | +<g>Transforming growth factor-beta1</g> in <d>sarcoidosis</d> | ||
| 337 | +The lncRNA <g>H19</g> | ||
| 338 | +<e>Contribution </e>of the anaphylatoxin receptors, <g>C3aR</g> and <g>C5aR</g>, to the pathogenesis of <d>pulmonary fibrosis</d> | ||
| 339 | +Corilagin attenuates aerosol bleomycin-induced experimental <d>lung injury</d> | ||
| 340 | +<g>TGF-b1</g> induces <g>tissue factor</g> expression in human lung fibroblasts in a <g>PI3K</g>/<g>JNK</g>/<g>Akt</g>-dependent and <g>AP-1</g>-dependent manner | ||
| 341 | +[Potential role of cytokines in <d>idiopathic pulmonary fibrosis</d>] | ||
| 342 | +Protective role of andrographolide in bleomycin-induced <d>pulmonary fibrosis</d> in mice | ||
| 343 | +Epithelial-mesenchymal transition in chronic <d>hypersensitivity pneumonitis</d> | ||
| 344 | +<g>Serpin B4</g> isoform overexpression is associated with aberrant epithelial proliferation and <d>lung cancer</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 345 | +Uncoupling of the profibrotic and hemostatic effects of <g>thrombin</g> in <d>lung fibrosis</d> | ||
| 346 | +Interstitial <d>fibrosis</d> and growth factors | ||
| 347 | +Molecular targets in <d>pulmonary fibrosis</d>: the myofibroblast in focus | ||
| 348 | +Immunomodulation by mesenchymal stem cells in treating human <d>autoimmune disease-associated lung fibrosis</d> | ||
| 349 | +<u>Reduced </u>transcription of the <g>Smad4</g> gene during <d>pulmonary carcinogenesis</d> in <d>idiopathic pulmonary fibrosis</d> | ||
| 350 | +Intrinsic defence capacity and therapeutic potential of natriuretic peptides in <d>pulmonary hypertension</d> associated with <d>lung fibrosis</d> | ||
| 351 | +<u>Blockade </u>of the Wnt/b-catenin pathway attenuates bleomycin-induced <d>pulmonary fibrosis</d> | ||
| 352 | +Curcumin inhibits <d>fibrosis</d>-related effects in <d>IPF</d> fibroblasts and in mice following bleomycin-induced <d>lung injury</d> | ||
| 353 | +<g>NADPH oxidase-4</g> mediates myofibroblast activation and fibrogenic responses to <d>lung injury</d> | ||
| 354 | +Anti-fibrotic Role of aB-crystallin Inhibition in Pleural and Subpleural <d>Fibrosis</d> | ||
| 355 | +Pleiotropic effect of the proton pump inhibitor esomeprazole leading to suppression of <d>lung inflammation</d> and <d>fibrosis</d> | ||
| 356 | +Reviews and prospectives of signaling pathway analysis in <d>idiopathic pulmonary fibrosis</d> | ||
| 357 | +Roles of p38 MAPK and <g>JNK</g> in <g>TGF-b1</g>-induced human alveolar epithelial to mesenchymal transition | ||
| 358 | +Control of virus reactivation arrests pulmonary herpesvirus-induced <d>fibrosis</d> in IFN-gamma receptor-<u>deficient </u>mice | ||
| 359 | +BALF N-acetylglucosaminidase and <g>beta-galactosidase</g> activities in <d>idiopathic pulmonary fibrosis</d> | ||
| 360 | +Predisposition for disrepair in the aged lung | ||
| 361 | +Possible involvement of pirfenidone metabolites in the antifibrotic action of a therapy for <d>idiopathic pulmonary fibrosis</d> | ||
| 362 | +N-acetylcysteine <u>downregulation </u>of <g>lysyl oxidase</g> activity alleviating bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
| 363 | +Evaluation of permeability alteration and epithelial-mesenchymal transition induced by <g>transforming growth factor-b1</g> in A549, NCI-H441, and Calu-3 cells: Development of an in vitro model of respiratory epithelial cells in <d>idiopathic pulmonary fibrosis</d> | ||
| 364 | +Epithelial contribution to the pro-fibrotic stiff microenvironment and myofibroblast population in lung <d>fibrosis</d> | ||
| 365 | +Interactions between <g>b-catenin</g> and <g>transforming growth factor-b</g> signaling pathways mediate epithelial-mesenchymal transition and are dependent on the transcriptional co-activator cAMP-response element-binding protein (<g>CREB)-binding protein</g> (<g>CBP</g>) | ||
| 366 | +BAL cytokine profile in different <d>interstitial lung diseases</d>: a focus on <d>systemic sclerosis</d> | ||
| 367 | +<g>Syndecan-2</g> is a novel target of <g>insulin-like growth factor binding protein-3</g> and is <v>over-expressed </v>in <d>fibrosis</d> | ||
| 368 | +Membrane-anchored <g>Serine Protease</g> <g>Matriptase</g> | ||
| 369 | +Interplay between <g>RAGE</g>, <g>CD44</g>, and focal adhesion molecules in epithelial-mesenchymal transition of alveolar epithelial cells | ||
| 370 | +Antifibrotic properties of receptor for advanced glycation end products in <d>idiopathic pulmonary fibrosis</d> | ||
| 371 | +Anti-fibrotic effects of nintedanib in lung fibroblasts derived from patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 372 | +The small heat-shock protein aB-crystallin is essential for the nuclear <l>localization </l>of <g>Smad4</g>: impact on <d>pulmonary fibrosis</d> | ||
| 373 | +Dysregulated Collagen Homeostasis by Matrix Stiffening and <g>TGF-b1</g> in Fibroblasts from <d>Idiopathic Pulmonary Fibrosis</d> | ||
| 374 | +Medical treatment for <d>pulmonary fibrosis</d>: current trends, concepts, and prospects | ||
| 375 | +Ambroxol hydrochloride in the management of <d>idiopathic pulmonary fibrosis</d>: Clinical trials are the need of the hour | ||
| 376 | +Combined <u>inhibition </u>of <g>TGFb</g> and PDGF signaling attenuates radiation-induced <d>pulmonary fibrosis</d> | ||
| 377 | +Diagnostic Values For Club Cell Secretory Protein (<g>CC16</g>) in Serum of Patients of Combined Pulmonary Fibrosis and Emphysema | ||
| 378 | +<e>Effects </e>of <g>thymosin b4</g> and its N-terminal fragment Ac-SDKP on <g>TGF-b</g>-treated human lung fibroblasts and in the mouse model of bleomycin-induced <d>lung fibrosis</d> | ||
| 379 | +Matrix metalloproteinase 3 is a mediator of <d>pulmonary fibrosis</d> | ||
| 380 | +An <u>inhibitor </u>of NADPH oxidase-4 attenuates established <d>pulmonary fibrosis</d> in a <d>rodent disease</d> model | ||
| 381 | +TGF-b1 T869C polymorphism may affect susceptibility to <d>idiopathic pulmonary fibrosis</d> and disease severity | ||
| 382 | +<g>Th1</g>/Th2 cytokine gene polymorphisms in patients with <d>idiopathic pulmonary fibrosis</d> | ||
| 383 | +<u>Inhibition </u>of <g>PI3K</g> prevents the proliferation and differentiation of human lung fibroblasts into myofibroblasts: the role of class I P110 isoforms | ||
| 384 | +<r>Effects </r>of doxycycline on <e>production </e>of growth factors and matrix metalloproteinases in <d>pulmonary fibrosis</d> | ||
| 385 | +Anti-pulmonary fibrotic activity of salvianolic acid B was screened by a novel method based on the cyto-biophysical properties | ||
| 386 | +Cytokines in human <d>lung fibrosis</d> | ||
| 387 | +Human placental mesenchymal stem cells of fetal origins-alleviated <d>inflammation</d> and <d>fibrosis</d> by attenuating <g>MyD88</g> signaling in bleomycin-induced <d>pulmonary fibrosis</d> mice | ||
| 388 | +Roles for <g>insulin-like growth factor I</g> and <g>transforming growth factor-beta</g> in <d>fibrotic lung disease</d> | ||
| 389 | +<e>Expression </e>of <g>RXFP1</g> | ||
| 390 | +Role of <g>caveolin-1</g> in <d>fibrotic diseases</d> | ||
| 391 | +Olodaterol shows anti-fibrotic efficacy in in vitro and in vivo models of <d>pulmonary fibrosis</d> | ||
| 392 | +Novel Mechanisms for the Antifibrotic Action of Nintedanib | ||
| 393 | +Plasma <g>CCN2</g> (connective tissue growth factor; <g>CTGF</g>) is a potential biomarker in <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
| 394 | +Azithromycin attenuates myofibroblast differentiation and lung <d>fibrosis</d> development through <d>proteasomal degradation</d> of <g>NOX4</g> | ||
| 395 | +Transforming Growth Factor (TGF)-b Promotes de Novo Serine Synthesis for Collagen <e>Production.</e> <g>TGF-b</g> <v>promotes </v>excessive collagen deposition in <d>fibrotic diseases</d> such as <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) | ||
| 396 | +Association between cytokine removal by polymyxin B hemoperfusion and improved pulmonary oxygenation in patients with acute exacerbation of <d>idiopathic pulmonary fibrosis</d> | ||
| 397 | +Crosstalk between <g>TGF-b1</g> and complement activation augments epithelial <d>injury in pulmonary fibrosis</d> | ||
| 398 | +[The morphology and molecular bases of damage to the stem cell niche of respiratory acini in <d>idiopathic interstitial pneumonias</d>] | ||
| 399 | +Pirfenidone inhibits myofibroblast differentiation and <d>lung fibrosis</d> development during insufficient mitophagy | ||
| 400 | +Bleomycin and <g>IL-1beta</g>-mediated <d>pulmonary fibrosis</d> is <g>IL-17A</g> dependent | ||
| 401 | +Insulin-like growth factor binding proteins 3 and 5 are <v>overexpressed </v>in <d>idiopathic pulmonary fibrosis</d> and contribute to extracellular matrix deposition | ||
| 402 | +<g>VEGF</g> ameliorates pulmonary <d>hypertension</d> through inhibition of endothelial apoptosis in experimental lung <d>fibrosis</d> in rats | ||
| 403 | +Rapamycin regulates connective tissue growth factor expression of lung epithelial cells via phosphoinositide 3-kinase | ||
| 404 | +miR-199a-5p Is <v>upregulated </v>during fibrogenic response to tissue injury and mediates TGFbeta-induced lung fibroblast activation by targeting <g>caveolin-1</g> | ||
| 405 | +Inhibition of mechanosensitive signaling in myofibroblasts ameliorates experimental <d>pulmonary fibrosis</d> | ||
| 406 | +Integrated analyses identify the involvement of microRNA-26a in epithelial-mesenchymal transition during <d>idiopathic pulmonary fibrosis</d> | ||
| 407 | +Differential <e>expression </e>of alpha E beta 7 integrins on bronchoalveolar lavage T lymphocyte subsets: <r>regulation </r>by alpha 4 beta 1-integrin crosslinking and <g>TGF-beta</g> | ||
| 408 | +<v>Increased </v><g>TGF-beta1</g> in the lungs of asbestos-exposed rats and mice: <u>reduced </u><e>expression </e>in <g>TNF-alpha</g> receptor knockout mice | ||
| 409 | +Fibrotic myofibroblasts manifest genome-wide derangements of translational control | ||
| 410 | +<g>Transforming growth factor beta1</g> induces epithelial-to-mesenchymal transition of A549 cells | ||
| 411 | +<r>Regulation </r>of <g>TGF-b</g> storage and activation in the human <d>idiopathic pulmonary fibrosis lung</d> | ||
| 412 | +The anti-fibrotic effects of microRNA-153 by <r>targeting </r><g>TGFBR-2</g> in <d>pulmonary fibrosis</d> | ||
| 413 | +<d>Microsatellite instability</d> in transforming growth factor-beta 1 type II receptor gene in alveolar lining epithelial cells of <d>idiopathic pulmonary fibrosis</d> | ||
| 414 | +miR-92a <r>regulates </r><g>TGF-b1</g>-<v>induced </v><g>WISP1</g> <e>expression </e>in <d>pulmonary fibrosis</d> | ||
| 415 | +<u>Inhibition </u>of <g>PHGDH</g> | ||
| 416 | +The role of cytokines in human <d>lung fibrosis</d> | ||
| 417 | +The Epstein-Barr virus latent membrane protein 1 and transforming growth factor--b1 synergistically induce epithelial--mesenchymal transition in lung epithelial cells | ||
| 418 | +Significant involvement of <g>CCL2</g> (<g>MCP-1</g>) in inflammatory disorders of the lung | ||
| 419 | +<g>TGF-beta</g>-induced EMT: mechanisms and implications for <d>fibrotic lung disease</d> | ||
| 420 | +Pirfenidone <u>inhibits </u><g>TGF-b1</g>-induced <e>over-expression </e>of collagen type I and <d>heat shock</d> protein 47 in A549 cells | ||
| 421 | +Bleomycin induces molecular changes directly relevant to <d>idiopathic pulmonary fibrosis</d>: a model for "active" disease | ||
| 422 | +<u>Defective </u>histone acetylation is <r>responsible </r>for the <u>diminished </u><e>expression </e>of <g>cyclooxygenase 2</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 423 | +y-Herpes virus-68, but not Pseudomonas aeruginosa or influenza A (H1N1), exacerbates <d>established murine lung fibrosis</d> | ||
| 424 | +The potential <r>role </r>of PDGF, <g>IGF-1</g>, <g>TGF-beta</g> <e>expression </e>in <d>idiopathic pulmonary fibrosis</d> | ||
| 425 | +Inhibition and role of <g>let-7d</g> in <d>idiopathic pulmonary fibrosis</d> | ||
| 426 | +Pleural mesothelial cell transformation into myofibroblasts and haptotactic migration in response to <g>TGF-beta1</g> in vitro | ||
| 427 | +Association of HLA and cytokine gene polymorphisms with <d>idiopathic pulmonary fibrosis</d> | ||
| 428 | +<g>Connective tissue growth factor</g> <e>expression </e>and <v>induction </v>by <g>transforming growth factor-beta</g> is <u>abrogated </u>by simvastatin via a Rho signaling mechanism | ||
| 429 | +MOXIBUSTION HAS A POSITIVE EFFECT ON PULMONARY FIBROSIS: AN ALTERNATIVE APPROACH | ||
| 430 | +Signaling pathways and their miRNA regulators involved in the etiopathology of <d>idiopathic pulmonary fibrosis</d> (<d>IPF</d>) and <d>hypersensitivity pneumonitis</d> (<d>HP</d>) | ||
| 431 | +Sustained Activation of <g>Toll-Like Receptor 9</g> | ||
| 432 | +<g>miR-21</g> mediates fibrogenic activation of pulmonary fibroblasts and lung <d>fibrosis</d> | ||
| 433 | +Molecular pathogenesis of <d>interstitial pneumonitis</d> with <g>TNF-alpha</g> transgenic mice | ||
| 434 | +<g>Transcription factor GATA-6</g> is <e>expressed </e>in quiescent myofibroblasts in <d>idiopathic pulmonary fibrosis</d> | ||
| 435 | +Inhibitory effects of amines from Citrus reticulata on bleomycin-induced <d>pulmonary fibrosis</d> in rats | ||
| 436 | +Thalidomide <u>reduces </u><g>IL-18</g>, <g>IL-8</g> and <g>TNF-alpha</g> <l>release </l>from alveolar macrophages in <d>interstitial lung disease</d> | ||
| 437 | +MiR-541-5p <r>regulates </r><d>lung fibrosis</d> by <r>targeting </r>cyclic nucleotide phosphodiesterase 1A | ||
| 438 | +The pathogenesis of <d>idiopathic pulmonary fibrosis</d> | ||
| 439 | +Effect of glycosides based standardized fenugreek seed extract in bleomycin-induced <d>pulmonary fibrosis</d> in rats: Decisive role of <g>Bax</g>, <g>Nrf2</g>, <g>NF-kB</g>, <g>Muc5ac</g>, <g>TNF-a</g> and <g>IL-1b</g> | ||
| 440 | +Participation of miR-200 in <d>pulmonary fibrosis</d> | ||
| 441 | +The Anti-fibrotic Effects and Mechanisms of MicroRNA-486-5p in <d>Pulmonary Fibrosis</d> | ||
| 442 | +<d>Autoimmunity</d> to Vimentin Is Associated with Outcomes of Patients with <d>Idiopathic Pulmonary Fibrosis</d> | ||
| 443 | +<g>TGF-beta 1</g>, but not <g>TGF-beta 2</g> or <g>TGF-beta 3</g>, is differentially present in epithelial cells of advanced <d>pulmonary fibrosis</d>: an immunohistochemical study | ||
| 444 | +Lysyl oxidases <r>regulate </r>fibrillar collagen remodelling in idiopathic pulmonary fibrosis | ||
| 445 | +Discovery and validation of extracellular/circulating microRNAs during <d>idiopathic pulmonary fibrosis disease</d> progression | ||
| 446 | +Recombinant human <g>serum amyloid P</g> in healthy volunteers and patients with <d>pulmonary fibrosis</d> | ||
| 447 | +<g>Gremlin</g>-mediated decrease in bone morphogenetic protein signaling promotes <d>pulmonary fibrosis</d> | ||
| 448 | +<v>Increased </v><e>expression </e>of <g>protease nexin-1</g> in fibroblasts during <d>idiopathic pulmonary fibrosis</d> <r>regulates </r><g>thrombin</g> activity and <g>fibronectin</g> <e>expression.</e> <d>Idiopathic pulmonary fibrosis</d> (<d>IPF</d>) is a chronic <d>diffuse lung disease</d> characterized by an accumulation of excess fibrous material in the lung | ||
| 449 | +The role of microRNA-155/liver X receptor pathway in experimental and <d>idiopathic pulmonary fibrosis</d> | ||
| 450 | +Hyper-responsiveness of <d>IPF</d>/<d>UIP</d> fibroblasts: interplay between <g>TGFbeta1</g>, <g>IL-13</g> and <g>CCL2</g> | ||
| 451 | +<d>Idiopathic pulmonary fibrosis</d> in relation to gene polymorphisms of <g>transforming growth factor-b1</g> and <g>plasminogen activator inhibitor 1</g> | ||
| 452 | +<g>TNF-alpha</g>, PDGF, and <g>TGF-beta(1)</g> <e>expression </e>by primary mouse bronchiolar-alveolar epithelial and mesenchymal cells: <g>tnf-alpha</g> induces <g>TGF-beta(1)</g> | ||
| 453 | +<g>Transforming Growth Factor Beta 1</g> | ||
| 454 | +Epithelial-to-mesenchymal transition and its role in <g>EGFR</g>-mutant <d>lung adenocarcinoma</d> and <d>idiopathic pulmonary fibrosis</d> | ||
| 455 | +<g>Cysteine-rich protein 1</g> is regulated by <g>transforming growth factor-b1</g> and expressed in lung <d>fibrosis</d> |
-
Please register or login to post a comment